Clinical trial · Interventional
Study of ZIO-101 in Multiple Myeloma
A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma
NCT00303199CI-TRIAL-00007502completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ZIO-101 (Darinaparsin) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single Arm
- interventionNames
- Drug: ZIO-101 (Darinaparsin)
Primary outcomes (3)
- measure
- Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03
- timeFrame
- 6 months
- measure
- Phase II efficacy using EMBT criteria.
- timeFrame
- 6 months
- measure
- Safety
- timeFrame
- 6 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.